RA Capital Management’s Jade Biosciences JBIO Stock Holding History

RA Capital Management’s Portfolio JBIO Stock Details JBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$81.6M	Hold	3,671,083	–	–	0.71%	29
2026 Q1	$51.6M	Hold	3,671,083	–	–	0.55%	34
2025 Q4	$56.6M	Buy	3,671,083 +2,608,757	+246%	+$30.6M	0.58%	33
2025 Q3	$9.17M	Hold	1,062,326	–	–	0.11%	52
2025 Q2	$10.6M	Buy	1,062,326 +799,695	+304%	+$27.2M	0.18%	44
2025 Q1	$23.1M	Hold	262,631	–	–	0.39%	38
2024 Q4	$24.4M	Hold	262,631	–	–	0.32%	52
2024 Q3	$19.2M	Hold	262,631	–	–	0.22%	55
2024 Q2	$15.3M	Buy	262,631 +26,517	+11%	+$17.6M	0.2%	55
2024 Q1	$244M	Hold	236,114	–	–	3.11%	5
2023 Q4	$187M	Hold	236,114	–	–	2.92%	6
2023 Q3	$112M	Hold	236,114	–	–	2.21%	8
2023 Q2	$142M	Hold	236,114	–	–	2.68%	7
2023 Q1	$167M	Hold	236,114	–	–	3.77%	5
2022 Q4	$242M	Hold	236,114	–	–	4.91%	3
2022 Q3	$137M	Hold	236,114	–	–	2.92%	6
2022 Q2	$129M	Hold	236,114	–	–	3.44%	4
2022 Q1	$151M	Hold	236,114	–	–	3.31%	3
2021 Q4	$97.4M	Hold	236,114	–	–	1.72%	16
2021 Q3	$173M	Hold	236,114	–	–	2.4%	10
2021 Q2	$189M	Buy	+236,114	New	+$189M	3.03%	6

Other funds holding JBIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RA Capital Management's JBIO Position: Q2 2026 in Review

RA Capital Management held its Jade Biosciences (JBIO) position steady in Q2 2026 at 3,671,083 shares worth $81.6M. The position accounts for 0.71% of the portfolio, ranked #29.

RA Capital Management first reported a position in JBIO in Q2 2021 and has held it in 21 quarters since. The position peaked at $244M in Q1 2024. 154 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

RA Capital Management held 3,671,083 shares of Jade Biosciences worth $81.6M as of Q2 2026.
RA Capital Management left its Jade Biosciences share count unchanged in Q2 2026.
Jade Biosciences made up 0.71% of RA Capital Management's portfolio in Q2 2026, its #29 holding.
RA Capital Management first reported a position in Jade Biosciences in Q2 2021 and has held it in 21 quarters since.
RA Capital Management's Jade Biosciences position peaked at $244M in Q1 2024.
154 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.